GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

This study was conducted to evaluate the effectiveness and tolerance of GDP (gemcitabine, dexamethasone, and cisplatin) regimen in patients with newly diagnosed stage IV and relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type (ENKTL). The study enrolled 41 ENKTL patients who re...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jing-jing, Dong, Mei, He, Xiao-hui, Li, Ye-xiong, Wang, Wei-hu, Liu, Peng, Yang, Jian-liang, Gui, Lin, Zhang, Chang-gong, Yang, Sheng, Zhou, Sheng-yu, Shi, Yuan-kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4753932/
https://www.ncbi.nlm.nih.gov/pubmed/26871836
http://dx.doi.org/10.1097/MD.0000000000002787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4753932/
https://www.ncbi.nlm.nih.gov/pubmed/26871836
http://dx.doi.org/10.1097/MD.0000000000002787

Ejemplares similares